Seema Irfan

Seema Irfan


Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 June 2008 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
SISeema Irfan
Seema Irfan
FIFaiza Idrees
Faiza Idrees
VMVikram Mehraj
Vikram Mehraj
FHFaizah Habib
Faizah Habib
SASalman Adil
Salman Adil
RHRumina Hasan
Rumina Hasan
This study was conducted to evaluate drug resistance amongst bacteremic isolates of febrile neutropenic patients with particular emphasis on emergence of carbapenem resistant Gram negative bacteria and vancomycin resistant Enterococcus species.

29 May 2009 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
AZAfia Zafar
Afia Zafar
FHFaiza Habib
Faiza Habib
RHRoshan Hadwani
Roshan Hadwani
MEMuslima Ejaz
Muslima Ejaz
KKKhurshid Khowaja
Khurshid Khowaja
SISeema Irfan
Seema Irfan
Accidental exposure to blood and body fluids is frequent among health care workers. They are at high risk of nosocomial transmission of blood borne pathogens due to injuries caused by used sharps. We are reporting impact of surveillance and educational program on the rate of needle stick injuries among health care workers at a tertiary care hospital in Pakistan.

14 June 2019 in Antimicrobial Resistance & Infection Control
Verified
Journal Article
Open access
PDF file
YSYusra Shafquat
Yusra Shafquat
KJKauser Jabeen
Kauser Jabeen
JFJoveria Farooqi
Joveria Farooqi
KMKiran Mehmood
Kiran Mehmood
SISeema Irfan
Seema Irfan
AZAfia Zafar
Afia Zafar
Globally metronidazole and carbapenem resistance in anaerobic organisms is increasing necessitating continuous surveillance to guide selection of empirical treatment. In this study we have determined metronidazole resistance in anaerobes using MIC Evaluator strips (M.I.C.E strips). Carbapenem resistance was evaluated only in metronidazole resistant isolates. The study was conducted at the Aga Khan University (AKU) Hospital laboratory, Karachi, Pakistan (2014–2017). Metronidazole and imipenem resistance was evaluated using M.I.C.E strips and minimum inhibitory concentrations (MICs) were interpreted using Clinical Laboratory Standards Institute (CLSI) criteria. Clinical details including demographics, prolonged hospital stay, malignancy, transplant, dialysis, diabetes, site of infection and outcome were analyzed for association with metronidazole resistance. Of the 223 clinically significant isolates, 39 (17.5%) were metronidazole resistant (excluding the inherently resistant organisms; for example Cutibacterium species). Imipenem resistance was determined in 29 metronidazole resistant isolates and of these 7 (24.1%) were found to be resistant. Proportion of metronidazole resistant strains was highest amongst Bacteroides species. A significant increase in metronidazole resistance from 12.3% in 2010–2011 to 17.5% in the current study was found. Carbapenem resistance also emerged in the period 2014–2017. Isolates from malignancy and transplant patients showed lower odds of developing metronidazole resistance (0.003(95% CI: 1.7–17.9)). Prolonged hospital stay was not associated with metronidazole resistance (1.1((95% CI: 0.5–2.5)). The rising trend of metronidazole resistance and emergence of carbapenem resistance in anaerobic bacteria is alarming. Continued surveillance with strengthening of laboratory capacity regarding anaerobic susceptibility testing is urgently needed in Pakistan.

1 January 2008 in Indian Journal of Medical Microbiology
Verified
Journal Article
Open access
PDF file
SISeema Irfan
Seema Irfan
AZA Zafar
A Zafar
DGD Guhar
D Guhar
TAT Ahsan
T Ahsan
RHR Hasan
R Hasan
Prompt detection of metallo-β-lactamase (MBL) producing isolates is necessary to prevent their dissemination. Frequency of MBLs producing strains among multidrug resistant (MDR) Acinetobacter species and Pseudomonas aeruginosa was evaluated in critical care patients using imipenem-EDTA disk method. One hundred MDR Acinetobacter spp. and 42 Pseudomonas aeruginosa were checked for MBL production, from January to June 2001. MBL was produced by 96.6 % of imipenem-resistant Acinetobacter isolates, whereas 100% imipenem-resistant Pseudomonas aeroginosa isolates were MBL producers. Carbapenem resistance in MDR Acinetobacter spp. and Pseudomonas aeruginosa isolates in this study was due to MBLs. This calls for strict infection control measures to prevent further dissemination.

1 June 2011 in Journal of Hospital Infection
Verified
Journal Article
Closed access
SISeema Irfan
Seema Irfan
Jane TurtonJane Turton
Jane Turton
JMJaishri Mehraj
Jaishri Mehraj
SSS.Z. Siddiqui
S.Z. Siddiqui
SHS. Haider
S. Haider
RHR. Hasan
R. Hasan

20 July 2024 in International Journal of Infectious Diseases
Verified
Journal Article
Open access
FQFarah Qamar
Farah Qamar
SQSonia Qureshi
Sonia Qureshi
ZHZoya Haq
Zoya Haq
TYTahir Yousafzai
Tahir Yousafzai
IQIbtisam Qazi
Ibtisam Qazi
JSJessica C. Seidman
Jessica C. Seidman
Typhoid remains a persistent contributor to childhood morbidity in communities lacking sanitation infrastructure. Typhoid conjugate vaccine (TCV) is effective in reducing disease risk in vaccinees; however, the duration of protection is unknown. This study measured the longevity of immune response to TCV in children aged under 10 years in Hyderabad, Pakistan, where an outbreak of extensively drug-resistant typhoid has been ongoing. A subset of children who received the TCV as part of the outbreak response were enrolled purposively from March 2018 to February 2019. The participants were followed up until January 2023. Blood samples were taken at baseline, 4-6 weeks, 6 months, and annually 1-4 years after vaccination to measure anti-Vi immunoglobulin (Ig) G levels using enzyme-linked immunosorbent assay. Active phone-based surveillance was performed to identify breakthrough infections. Blood culture was offered to any child with a history of fever ≥3 days within the last 7 days. A total of 81 children received a second dose of TCV in November 2019 during a catch-up campaign organized by the Sindh government. Nearly all participants seroconverted (802 of 837; 95.8%) at 4-6 weeks after vaccination. A total of 4 years after vaccination, 438 of 579 (75.6%) participants remained above the seroconversion threshold. The geometric mean titer (U/mL) of anti-Vi IgG at 4-6 weeks was 832.6 (95% confidence interval [CI]: 768.0-902.6); at 4 years after vaccination, the geometric mean titers in children aged 6 months to 2 years (12.6, [95% CI: 9.8-16.3]) and >2-5 years (40.1, [95% CI: 34.4-46.6]) were lower than in children aged >5-10 years (71.1, [95% CI: 59.5-85.0]). During 4 years of follow-up, nine children had culture-confirmed Salmonella Typhi infection; these infections occurred after a median duration of 3.4 years. All enteric fever cases seroconverted at 4-6 weeks after vaccination and seven (70.0%) remained seroconverted 4 years after vaccination. We observed 95.8% seroconversion after a single dose of TCV. There was a decay in anti-Vi IgG titers, and, at 4 years, approximately 75.6% remained seroconverted. There was a faster decay in children aged ≤2 years. Breakthrough infections were documented after a median 3.4 years after vaccination.